Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $1.73M worth of Intellia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Intellia Therapeutics, Inc. have bought $0 and sold $62.95M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $235,750 was made by SCHIERMEIER ANDREW (EVP, Dev and Corp Strategy) on 2019‑03‑06.
2024-06-17 | Sale | Verwiel Frank | director | 1,505 0.0016% | $25.00 | $37,625 | -3.77% | |
2024-03-04 | Sale | BASTA JAMES | EVP, General Counsel | 2,297 0.0024% | $32.99 | $75,778 | -23.10% | |
2024-03-04 | Sale | Clark Eliana | EVP, Chief Technical Officer | 605 0.0006% | $32.99 | $19,959 | -23.10% | |
2024-01-08 | Sale | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 2,275 0.0025% | $28.87 | $65,682 | -14.91% | |
2024-01-03 | Sale | LEONARD JOHN M | President and CEO | 19,223 0.0215% | $29.46 | $566,310 | -12.78% | |
2024-01-03 | Sale | Lebwohl David | EVP, Chief Medical Officer | 5,843 0.0065% | $29.46 | $172,135 | -12.78% | |
2024-01-03 | Sale | BASTA JAMES | EVP, General Counsel | 3,805 0.0043% | $29.46 | $112,095 | -12.78% | |
2024-01-03 | Sale | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 5,532 0.0062% | $29.46 | $162,973 | -12.78% | |
2024-01-03 | Sale | Clark Eliana | EVP, Chief Technical Officer | 4,608 0.0052% | $29.50 | $135,954 | -12.78% | |
2024-01-03 | Sale | Goddard Glenn | EVP, Chief Financial Officer | 5,365 0.006% | $29.46 | $158,053 | -12.78% | |
2024-01-03 | Sale | Hicks Derek | EVP, Chief Business Officer | 3,877 0.0043% | $29.46 | $114,216 | -12.78% | |
2023-10-31 | Sale | Bhanji Muna | director | 265 0.0003% | $23.90 | $6,334 | +5.21% | |
2023-07-31 | Sale | Bhanji Muna | director | 265 0.0003% | $42.33 | $11,217 | -34.37% | |
2023-07-06 | Sale | Bhanji Muna | director | 1,867 0.0021% | $39.30 | $73,373 | -27.66% | |
2023-07-03 | Sale | Clark Eliana | EVP, Chief Technical Officer | 360 0.0004% | $40.51 | $14,584 | -30.41% | |
2023-06-20 | Sale | Clark Eliana | EVP, Chief Technical Officer | 5,000 0.0059% | $45.00 | $225,000 | -34.07% | |
2023-03-02 | Sale | BASTA JAMES | EVP, General Counsel | 1,088 0.0012% | $43.88 | $47,741 | -18.13% | |
2023-01-05 | Sale | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 2,330 0.0026% | $38.48 | $89,659 | -2.68% | |
2023-01-04 | Sale | LEONARD JOHN M | President and CEO | 6,673 0.0072% | $37.21 | $248,302 | -3.48% | |
2023-01-04 | Sale | Lebwohl David | EVP, Chief Medical Officer | 2,574 0.0028% | $37.21 | $95,779 | -3.48% |
LEONARD JOHN M | President and CEO | 846486 0.9452% | $22.91 | 0 | 24 | |
Lebwohl David | EVP, Chief Medical Officer | 54372 0.0607% | $22.91 | 0 | 8 | |
BASTA JAMES | EVP, General Counsel | 81571 0.0575% | $22.91 | 0 | 4 | |
Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 43927 0.0491% | $22.91 | 0 | 7 | |
Clark Eliana | EVP, Chief Technical Officer | 71470 0.0456% | $22.91 | 0 | 6 | |
Goddard Glenn | EVP, Chief Financial Officer | 40585 0.0453% | $22.91 | 0 | 7 | |
Hicks Derek | EVP, Chief Business Officer | 36987 0.0413% | $22.91 | 0 | 2 | |
Verwiel Frank | director | 17948 0.0186% | $22.91 | 0 | 1 | |
Bhanji Muna | director | 11996 0.0134% | $22.91 | 0 | 3 | |
Novartis Institutes for BioMedical Research, Inc. | 10 percent owner | 4129903 4.6116% | $22.91 | 1 | 1 | <0.0001% |
Caribou Biosciences, Inc. | 10 percent owner | 3994355 4.4602% | $22.91 | 0 | 2 | |
Atlas Venture Fund IX, L.P. | 10 percent owner | 3579788 3.9973% | $22.91 | 0 | 3 | |
GORDON CARL L | director | 2662180 2.9727% | $22.91 | 1 | 0 | <0.0001% |
ORBIMED ADVISORS LLC | director | 2662180 2.9727% | $22.91 | 1 | 0 | <0.0001% |
BAKER BROS. ADVISORS LP | 976214 1.0901% | $22.91 | 1 | 0 | <0.0001% | |
Temasek Holdings (Private) Ltd | 10 percent owner | 790527 0.8827% | $22.91 | 1 | 0 | <0.0001% |
Bermingham Nessan | President & CEO | 458250 0.5117% | $22.91 | 0 | 3 | |
Rivera Jose E | EVP, General Counsel | 131032 0.1463% | $22.91 | 0 | 14 | |
SCHIERMEIER ANDREW | EVP, Chief Operating Officer | 16656 0.0186% | $22.91 | 1 | 1 | <0.0001% |
FORMELA JEAN FRANCOIS | director | 10000 0.0112% | $22.91 | 0 | 18 | |
DORSA CAROLINE | director | 5410 0.006% | $22.91 | 0 | 1 | |
KARSEN PERRY A | director | 5000 0.0056% | $22.91 | 0 | 1 | |
Crowley John F | director | 2094 0.0023% | $22.91 | 0 | 2 | |
Atlas Venture Associates IX, L.P. | 10 percent owner | 0 0% | $22.91 | 0 | 2 |
ARK Investment Management LLC | $302.32M | 11.39 | 10.99M | -3.71% | -$11.64M | 2.11 | |
BlackRock | $250.6M | 9.44 | 9.11M | +1.09% | +$2.71M | 0.01 | |
The Vanguard Group | $250.17M | 9.43 | 9.09M | +8.94% | +$20.53M | 0.01 | |
State Street | $126.49M | 4.77 | 4.6M | -2.92% | -$3.8M | 0.01 | |
Deep Track Capital Lp | $115.84M | 4.37 | 4.21M | +87.15% | +$53.94M | 0.53 | |
Wellington Management Company | $114.5M | 4.31 | 4.16M | +69.41% | +$46.91M | 0.02 | |
Sumitomo Mitsui Trust Holdings | $93.52M | 3.52 | 3.4M | -2.28% | -$2.18M | 0.06 | |
Nikko Asset Management Americas Inc | $93.38M | 3.52 | 3.4M | -2.28% | -$2.18M | 0.89 | |
Morgan Stanley | $72.76M | 2.74 | 2.64M | +3.92% | +$2.75M | 0.01 | |
Fidelity Investments | $60.7M | 2.29 | 2.21M | +85.94% | +$28.05M | <0.01 | |
Geode Capital Management | $56.25M | 2.12 | 2.04M | +3.6% | +$1.95M | 0.01 | |
Federated Hermes | $53.09M | 2 | 1.93M | -4.29% | -$2.38M | 0.12 | |
Casdin Capital | $51.58M | 1.94 | 1.88M | +29.31% | +$11.69M | 3.84 | |
T. Rowe Price | $44.71M | 1.68 | 1.63M | -11.4% | -$5.75M | 0.01 | |
AllianceBernstein | $43.23M | 1.63 | 1.57M | -5.54% | -$2.54M | 0.02 | |
Rokos Capital Management | $40.21M | 1.52 | 1.46M | 0% | +$0 | 1.05 | |
Contrarius Investment Management Ltd | $37.15M | 1.4 | 1.35M | +529.91% | +$31.25M | 2.15 | |
Dimensional Fund Advisors | $33.72M | 1.27 | 1.23M | +4.69% | +$1.51M | 0.01 | |
Chevy Chase Trust Holdings Inc | $29.56M | 1.11 | 1.07M | +8.42% | +$2.3M | 0.1 | |
Goldman Sachs | $29.37M | 1.11 | 1.07M | +29.46% | +$6.68M | 0.01 | |
Himension Capital Singapore Pte Ltd | $28.35M | 1.07 | 1.03M | 0% | +$0 | 2.13 | |
Citadel Advisors LLC | $24.51M | 0.92 | 890,784 | -29.26% | -$10.14M | 0.02 | |
Northern Trust | $23.97M | 0.9 | 871,295 | -1.7% | -$415,208.42 | <0.01 | |
Voloridge Investment Management, LLC | $21.88M | 0.83 | 795,514 | +2,292.09% | +$20.97M | 0.05 | |
Charles Schwab | $20.04M | 0.76 | 728,295 | +4.01% | +$772,123.19 | 0.01 | |
Two Sigma Advisers LP | $18.14M | 0.68 | 659,317 | +42.09% | +$5.37M | 0.03 | |
Bank of America | $17.23M | 0.65 | 626,423 | +64.94% | +$6.79M | <0.01 | |
Two Sigma | $16.91M | 0.64 | 614,568 | +21% | +$2.93M | 0.03 | |
Discovery Value Fund | $15.45M | 0.58 | 561,561 | 0% | +$0 | 5.35 | |
JPMorgan Chase | $14.94M | 0.56 | 543,107 | -14.62% | -$2.56M | <0.01 | |
Bioimpact Capital Llc | $11.9M | 0.45 | 432,598 | +13.07% | +$1.38M | 1.93 | |
Vestmark Advisory Solutions Inc | $11.57M | 0.44 | 420,397 | +58.05% | +$4.25M | 0.67 | |
Nuveen | $10.56M | 0.4 | 383,868 | -19.31% | -$2.53M | <0.01 | |
Ubs Asset Management Americas Inc | $10.44M | 0.39 | 379,638 | -12.12% | -$1.44M | <0.01 | |
BNY Mellon | $9.96M | 0.38 | 362,005 | -8.03% | -$869,042.07 | <0.01 | |
Citigroup | $9.43M | 0.36 | 342,966 | +104.63% | +$4.82M | 0.01 | |
Marshall Wace | $9.23M | 0.35 | 335,408 | -62.34% | -$15.27M | 0.01 | |
UBS | $9.12M | 0.34 | 331,586 | +20.79% | +$1.57M | <0.01 | |
Rafferty Asset Management Llc | $8.9M | 0.34 | 323,561 | -1.65% | -$149,571.87 | 0.03 | |
Temasek Holdings | $7.69M | 0.29 | 279,693 | 0% | +$0 | 0.04 | |
American Century Investments | $7.34M | 0.28 | 266,964 | +7.42% | +$507,146.88 | <0.01 | |
Pinnacle Associates, Ltd. | $7.03M | 0.27 | 255,716 | New | +$7.03M | 0.11 | |
Opaleye Management Inc | $7.02M | 0.26 | 255,000 | +157.58% | +$4.29M | 1.11 | |
Hudson Bay Capital Management LP | $6.8M | 0.26 | 247,300 | +4.13% | +$269,598.00 | 0.07 | |
Squarepoint Ops LLC | $6.76M | 0.26 | 245,776 | +2,348.7% | +$6.49M | 0.03 | |
Healthcare Of Ontario Pension Plan Trust Fund | $6.55M | 0.25 | 238,000 | -20.13% | -$1.65M | 0.02 | |
PDT Partners | $6.13M | 0.23 | 222,971 | +38.49% | +$1.7M | 0.46 | |
Granahan Investment Management | $6.06M | 0.23 | 220,219 | -14.57% | -$1.03M | 0.21 | |
Mirae Asset Global Investments Co Ltd | $7.73M | 0.23 | 217,394 | +16.97% | +$1.12M | 0.01 | |
Wells Fargo | $5.94M | 0.22 | 215,758 | +6.5% | +$362,141.97 | <0.01 |